Drug Trial Radar · NCT04843098
Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
May 26, 2021
Primary completion
Nov 20, 2024
Study completion Apr 23, 2025
Sponsor
- Lead sponsor
- Suzhou Junde Biotechnology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, pharmacokinetic and efficacy of TL117 plus paclitaxel in patients with recurrent or metastatic head and neck cancer.
Conditions
- Head and Neck Squamous Cell Carcinoma
Interventions
TL117Drug
TL117 capsules orally once daily
PaclitaxelDrug
Paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 28-day treatment cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ia -Dose Limiting Toxicity (DLT) of TL117 treatmentTime frame: From time of the first dosing to time of Cycle 1 Day 28(each cycle is 28 days)
- Phase Ib -Dose Limiting Toxicity (DLT) of TL117 plus paclitaxel combination treatmentTime frame: From time of the first dosing to time of Cycle 1 Day 28(each cycle is 28 days)
- Phase II - Objective response rate (ORR)Time frame: Every 8 weeks from date of first treatment until date of last treatment up to 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.